lymphoid cells

[Blood] MB1-47 treatment in T cell acute lymphoblastic leukemia cells robustly inhibited cell proliferation via both cytostatic and cytotoxic effects as a result of compromised mitochondrial energy and metabolite depletion, which severely impaired nucleotide biosynthesis.

[Blood] Researchers showed that transcriptional downregulation of PU.1 was an active process involving an alternative promoter in intron 3 that was induced by RUNX transcription factors driving noncoding antisense transcription.

[Blood Advances] Scientists reported the long‐term safety and efficacy of the hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen in adults with Burkitt leukemia and high-grade B-cell lymphoma, focusing on its efficacy to prevent CNS relapse.

[LAVA Therapeutics N.V.] LAVA Therapeutics N.V. announced that the US FDA has granted orphan drug designation for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.

[eLife] Researchers conducted a longitudinal study of infection-naïve and COVID-19 convalescent donors before vaccination and after their first and second vaccine doses, using a high-parameter CyTOF analysis to phenotype their SARS-CoV-2-specific T cells.

[Science] The authors longitudinally profiled vaccine responses in SARS-CoV-2 naïve and recovered individuals for six months after vaccination.